Oncology
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Bluestar Genomics, Inc., an early cancer detection company leading the development and commercialization of next-generation liquid biopsy approaches initially focused on non-invasive detection of high-mortality cancers, today announced positive performance evaluation study results for its pancreatic cancer test. These data confirm that its pancreatic cancer test detects the…
Read More
— Single-cell proteomics can elucidate kinase activity in prostate cancer models — — Kinase activity in bone metastases and epithelial circulating tumor cells is elevated — Excerpt from the Press Release: BEVERLY, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) — TellBio, Inc., a development stage biotechnology company focused on revolutionizing the detection of cancer through its…
Read More
– FDA lifts partial clinical hold following agreement on mitigation strategy for differentiation syndrome – – KOMET-001 study to resume screening and enrollment of new patients – – Encouraging safety, tolerability and clinical activity observed among patients on study – Excerpt from the Press Release: SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) — Kura Oncology,…
Read More
Five-year collaboration to provide support for clinical and preclinical efforts as Yingli Pharma expands its U.S. presence with robust oncology pipeline Excerpt from the Press Release: SAN FRANCISCO and HOUSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) — Yingli Pharma US, Inc. (the “Company” or “Yingli”), a biotechnology company developing innovative small molecules, and The University of…
Read More
Excerpt from the Press Release: BRISBANE, Calif. and ST. LOUIS, Jan. 21, 2022 (GLOBE NEWSWIRE) — Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 biologic therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to AO-176 on January 3rd, 2022, for the…
Read More
Excerpt from the Press Release: WALTHAM, Mass. & LAKELAND, Fla.–(BUSINESS WIRE)–BostonGene Corporation and WellDyne today announced a strategic partnership to improve therapeutic decision-making for cancer patients. With BostonGene Tumor Portrait™ Tests, WellDyne will increase efficiency and therapy selection for patients who are candidates for immunotherapy in melanoma, non-small cell lung cancer, gastric, bladder and kidney…
Read More
The new company is focused on developing GP-2250, a novel cancer therapeutic with a unique mechanism of action Excerpt from the Press Release: Panavance Therapeutics Inc. (“Panavance”) is a new clinical-stage pharmaceutical company created to advance and develop GP-2250, a patented, novel therapeutic for the treatment of cancer and other therapeutic indications. GP-2250 is a…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune disease, today announced that the first…
Read More
— Phase 2/3 GRANITE-CRC-1L trial has registrational intent — — Updated data from Phase 1/2 trial in end-stage metastatic MSS-CRC further support the association of circulating tumor DNA (ctDNA) reduction with extended overall survival — — GRANITE has received Fast Track designation by the U.S. Food and Drug Administration for the treatment of MSS-CRC –…
Read More
Excerpt from the Press Release: REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that the first patient has…
Read More